Evidence map›Paper›PMID 28729850›Full record

ReviewFrontiers in neurology2017

Drug-Resistant Epilepsy: Multiple Hypotheses, Few Answers.

Fei Tang, Anika M S Hartz, Björn Bauer

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 212 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
212citing papers in PubMed, 7 pooled it
16.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

212 citing papers in PubMed, 7 syntheses or guidelines pooled it, 473 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. MicroRNAs in temporal lobe epilepsy: a systematic review.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021
    Pooled it
  8. Trial
  9. Review
  10. Article
  11. Article
  12. Article
  13. Molecules (Basel, Switzerland) · 2026
    Article
  14. Article
  15. Genetic Polymorphisms inPharmaceuticals (Basel, Switzerland) · 2026
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

152 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Fei TangDepartment of Pharmacy Practice and Pharmaceutical Sciences, College of Pharmacy, University of Minnesota, Duluth, MN, United States.
Anika M S HartzSanders-Brown Center on Aging, University of Kentucky, Lexington, KY, United States.
Björn BauerDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY, United States.
University of Kentucky · USUniversity of Minnesota, Duluth · US

Funding

Novel Therapeutic Strategies to Resolve Neurovascular Inflammation and Repair Blood-Brain Barrier Dysfunction in EpilepsyR01NS079507 · NINDS · UNIVERSITY OF MINNESOTA · PI BAUER, BJOERN · 2012 to 2025
$4.5M
NINDS NIH HHS R01 NS079507
6 · The paper itself

Abstract

Epilepsy is a common neurological disorder that affects over 70 million people worldwide. Despite the recent introduction of new antiseizure drugs (ASDs), about one-third of patients with epilepsy have seizures refractory to pharmacotherapy. Early identification of patients who will become refractory to ASDs could help direct such patients to appropriate non-pharmacological treatment, but the complexity in the temporal patterns of epilepsy could make such identification difficult. The target hypothesis and transporter hypothesis are the most cited theories trying to explain refractory epilepsy, but neither theory alone fully explains the neurobiological basis of pharmacoresistance. This review summarizes evidence for and against several major theories, including the pharmacokinetic hypothesis, neural network hypothesis, intrinsic severity hypothesis, gene variant hypothesis, target hypothesis, and transporter hypothesis. The discussion is mainly focused on the transporter hypothesis, where clinical and experimental data are discussed on multidrug transporter overexpression, substrate profiles of ASDs, mechanism of transporter upregulation, polymorphisms of transporters, and the use of transporter inhibitors. Finally, future perspectives are presented for the improvement of current hypotheses and the development of treatment strategies as guided by the current understanding of refractory epilepsy.

Indexed as

blood–brain barrierepilepsyP-glycoproteinrefractory epilepsytarget hypothesistransporter hypothesistransporter inhibitiontransporter regulation

Identifiers

PMID28729850
PMCPMC5498483
OpenAlexW2726666234

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.